Trial ID or NCT#

NCT03443024

Status

NOT RECRUITING

Purpose

The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in patients with moderate-to-severe atopic dermatitis.

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Justin M Ko, MD, MBA
Dermatologist, Melanoma specialist, Cutaneous oncology specialist, Hair loss specialist, Psoriasis specialist
Clinical Associate Professor, Dermatology

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM